Stratec (SBS) Health Care Conference summary

Business model and technology

• Customizes proprietary technology for OEM partners, integrating IP into instruments and consumables, ensuring recurring revenue through minimum purchase obligations.

• Focuses on automation in diagnostics and life sciences, with 50,000 analyzer systems in the field generating significant recurring revenue from consumables and service parts.

• Recurring revenue from consumables and maintenance parts now exceeds instrument sales, representing 43% of 2024 revenue.

• Invests heavily in R&D, with nearly half of 1,500 employees dedicated to innovation.

• Offers full integration from hardware to software, including IoT and cybersecurity solutions.

Market position and customer base

• Partners with 16 of the top 20 diagnostics companies, with room to expand programs within existing accounts.

• Addresses both large established players and innovation-driven companies, targeting niche and core products.

• Install base growth is a key driver for recurring revenue, with a strong focus on molecular diagnostics, immunoassay, and hematology.

• Market is not saturated; significant growth potential remains with current and new partners.

Financial performance and outlook

• Achieved a 13.13% CAGR in revenue since IPO in 1998, with robust income growth.

• 2024 saw a shift: instrument sales dropped to 32% of revenue, while consumables and service parts rose due to post-COVID market dynamics.

• Expects instrument sales to recover as molecular segment normalizes and replacement cycles accelerate.

• 2025 guidance: low to mid single-digit sales growth, adjusted EBIT margin of 10-12% (down from 13% in 2024), with a focus on cost discipline and investment in adjacent areas.

• Maintains a well-filled M&A pipeline, seeking attractive targets amid industry consolidation.